+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 55Years +
All Genders
ID06946602

Comparing Two Conditioning Regimens Before Haploidentical Stem Cell Transplant in Elderly AML Patients to Reduce Transplant Risks

Led by Peking University People's Hospital · Updated on 2026-09-14

307

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Elderly patients with acute myeloid leukemia AML typically have a poor outlook when treated with conventional chemotherapy. Allogeneic hematopoietic stem cell transplantation allo-HSCT can improve long-term survival but is limited by high transplantation-related mortality TRM. Current research aims to reduce TRM in elderly AML patients by optimizing conditioning regimens before transplantation. This study compares two conditioning regimens, BuFluCyATG and BuCyATG, to evaluate their impact on TRM in elderly AML patients undergoing haploidentical HSCT. The study evaluates two conditioning regimens given before haploidentical hematopoietic stem cell transplantation. The BuFluCyATG regimen involves a combination of Ara-C, busulfan, fludarabine, cyclophosphamide, and ATG administered intravenously over specific days before transplantation. The BuCyATG regimen uses Ara-C, busulfan, cyclophosphamide, and ATG with different dosing schedules. Participants will be randomly assigned to receive one of these regimens to determine if the BuFluCyATG regimen reduces TRM compared to BuCyATG. Participants will be followed from transplantation through 12 months post-treatment to monitor transplant-related mortality, toxicity of conditioning at 28 and 100 days, engraftment, graft-versus-host disease GVHD, overall survival, relapse rates, leukemia-free survival, event-free survival, and viral infections. The study includes assessments such as blood tests and clinical evaluations during this follow-up period to measure these outcomes and evaluate safety and effectiveness.

CONDITIONS

Brief Title

Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.

Research Team

Y

Yuqian Sun

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here